title: Small ubiquitin-like modifier 4 M55V polymorphism is not associated with diabetic nephropathy in Iranian type 2 diabetes patients.
abstract: BACKGROUND
  We studied the impact of small ubiquitin-like modifier 4 (SUMO4) M55V polymorphism on susceptibility to diabetic nephropathy in Iranian type 2 diabetes patients.
  
  
  METHODS
  The patient group consisted of 50 Iranian type 2 diabetes patients with nephropathy, and the control group consisted of 50 Iranian type 2 diabetes patients without nephropathy. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism method for the M55V.
  
  
  RESULTS
  The frequency of SUMO4 AA, AG, and GG genotypes were 23%, 18%, and 9% in the patient group and 10%, 22%, and 18% in the control group. There was no significant difference in frequency of SUMO4 genotypes in patients compared to controls.
  
  
  CONCLUSIONS
  These findings indicate that SUMO4 M55V polymorphism is not associated with diabetic nephropathy in Iranian type 2 diabetes patients.
authors.affiliation: Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran.
authors.forename: Farhad
authors.initials: F
authors.lastname: Shahsavar
authors.forename: Mehrzad
authors.initials: M
authors.lastname: Jafarzadeh
authors.forename: Alireza
authors.initials: A
authors.lastname: Azargoon
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hedayati
authors.forename: Behnam
authors.initials: B
authors.lastname: Asadifar
keywords: Iranian; nephropathy; polymorphism; small ubiquitin-like modifier 4; type 2 diabetes
references.citation: J Clin Endocrinol Metab. 2007 Jun;92(6):2358-62
references.pmid: 17374705
references.citation: N Engl J Med. 1989 May 4;320(18):1161-5
references.pmid: 2710189
references.citation: J Biol Chem. 2004 Jun 25;279(26):27233-8
references.pmid: 15123604
references.citation: J Am Soc Nephrol. 2002 Apr;13(4):894-902
references.pmid: 11912248
references.citation: Diabetes Care. 2000 Jan;23 Suppl 1:S4-19
references.pmid: 12017675
references.citation: N Engl J Med. 1999 Oct 7;341(15):1127-33
references.pmid: 10511612
references.citation: J Mol Biol. 1998 Jul 10;280(2):275-86
references.pmid: 9654451
references.citation: Nat Genet. 2004 Aug;36(8):837-41
references.pmid: 15247916
references.citation: Diabetes. 2007 Apr;56(4):1177-80
references.pmid: 17229939
references.citation: Diabetes. 2006 May;55(5):1252-9
references.pmid: 16644679
references.citation: Biochem Biophys Res Commun. 2005 Nov 18;337(2):517-20
references.pmid: 16198310
references.citation: Hum Mol Genet. 1996 Jul;5(7):1071-4
references.pmid: 8817350
references.citation: Mol Cell. 1998 Aug;2(2):233-9
references.pmid: 9734360
references.citation: Ann N Y Acad Sci. 2006 Oct;1079:257-67
references.pmid: 17130563
references.citation: Diabetes. 2000 Jun;49(6):1049-56
references.pmid: 10866059
references.citation: Diabetes. 2007 Aug;56(8):e11; author reply e12-3
references.pmid: 17660269
references.citation: J Am Soc Nephrol. 2004 Aug;15(8):2139-51
references.pmid: 15284299
references.citation: Gene. 2002 Aug 21;296(1-2):65-73
references.pmid: 12383504
references.citation: Diabetes Res Clin Pract. 2010 Nov;90(2):191-5
references.pmid: 20728233
references.citation: J Biol Chem. 2001 Nov 9;276(45):41661-7
references.pmid: 11518704
references.citation: Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):14-7
references.pmid: 17926234